Cipaglucosidase Alfa/Miglustat Therapy Improves Efficacy Outcomes in Enzyme Replacement Therapy-Experienced Patients With Late-Onset Pompe Disease

A new analysis of the phase 3 PROPEL study showed that switching to cipaglucosidase alfa/miglustat therapy enhanced outcomes among patients with late-onset Pompe disease.:

Source: Neurology Read More

Previous PostNeuroVoices: John Winkelman, MD, PhD, on Taking a Major Shift Away From Dopamine Agonists in the Revised Guidelines for Restless Leg Syndrome Treatment
Next PostMeta-Analysis Reveals Significant Burden of Cardiovascular Comorbidities in Myasthenia Gravis

Cipaglucosidase Alfa/Miglustat Therapy Improves Efficacy Outcomes in Enzyme Replacement Therapy-Experienced Patients With Late-Onset Pompe Disease

Previous PostNeuroVoices: John Winkelman, MD, PhD, on Taking a Major Shift Away From Dopamine Agonists in the Revised Guidelines for Restless Leg Syndrome Treatment

Next PostMeta-Analysis Reveals Significant Burden of Cardiovascular Comorbidities in Myasthenia Gravis

Related Posts

<![CDATA[Group-Based Resilience Program Improves Psychological Outcomes in Multiple Sclerosis]]>

<![CDATA[Qihuang Needle Acupuncture Improves Motor and Nonmotor Parkinson Disease Symptoms]]>

<![CDATA[World Alzheimer Day: Notable Clinical Interviews From 2026]]>

Categories